文献速递牙周病

类风湿关节炎患者牙周治疗结局:OPERA可行性随机试验

Outcomes of periodontal therapy in rheumatoid arthritis: The OPERA feasibility randomized trial.
PubMed 文献 · J Clin Periodontol · 2022-12-16

本研究为可行性随机对照试验,纳入60例活动性类风湿关节炎(RA)合并牙周炎患者,随机分为立即强化牙周治疗组和延迟治疗对照组。结果显示牙周治疗与牙周炎症表面积、累积探诊深度、RA疾病活动度评分及超声评分降低相关,但临床附着丧失无变化。试验整体可行且为患者所接受,但招募和保留具有挑战性。

要点

  • 牙周治疗可降低RA合并牙周炎患者的牙周炎症表面积和累积探诊深度。
  • 牙周治疗与RA疾病活动度评分(DAS28-CRP)及超声评分降低相关。
  • 临床附着丧失(CAL)在试验期间无变化,部分病例牙周炎症完全消退困难。

核心结论

  • 在RA合并牙周炎患者中,牙周治疗使牙周疾病结局和整体RA疾病活动度获得显著改善,但部分病例牙周炎症完全消退困难。
  • 该随机对照试验在RA患者中评估牙周治疗对RA影响是可行且可接受的,但招募和满意保留具有挑战性。

研究设计与样本

  • 可行性随机对照临床试验,纳入RA合并牙周炎患者,随机分为立即强化牙周治疗组(30例)和延迟治疗对照组(30例),由牙科保健员在二级护理机构实施。
  • 纳入标准:RA合并牙周炎、年龄18岁以上、疾病修饰抗风湿药稳定治疗≥3个月、DAS28≥3.2,仅当患者不愿使用生物制剂时DAS28>5.1。
  • 在基线及随访3个月和6个月时收集数据;对照组在试验期间接受标准护理(包括口腔卫生指导),研究完成后(随机化后6个月)接受与干预组相同的牙周治疗。

主要发现

  • 共邀请649例RA患者,296例(46%)同意参加筛选访视,201例评估合格性,其中41例(20%)不符合RA纳入标准,100例(50%)不符合牙周病标准,60例(30%)合格参与者随机分组。
  • 试验结束时失访率为18%。
  • 组间基线特征无重大差异。
  • 牙周治疗与牙周炎症表面积、累积探诊深度、RA疾病活动度评分及超声评分降低相关。
  • 临床附着丧失(CAL)无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Periodontitis is independently associated with rheumatoid arthritis (RA); however, there is limited data on whether periodontal treatment improves overall RA disease activity. We conducted a pilot feasibility randomized controlled clinical trial to test whether intensive periodontal therapy reduces RA disease activity in patients with active RA and periodontitis. MATERIALS AND METHODS: The following inclusion criteria were applied: patients with RA and periodontitis, aged 18+, stable on treatment with disease-modifying anti-rheumatic drugs for ≥3 months, disease activity score (DAS28) ≥3.2, and DAS28 >5.1 only if patient unwilling to take biologics. Participants meeting the inclusion criteria were randomized to immediate intensive periodontal therapy or to delayed therapy (control group) administered by a dental hygienist in a secondary care setting. Data were collected at baseline and at 3 and 6 months of follow-up. Participants randomized to the control group (delayed therapy) received the standard of care for the duration of the trial, including oral hygiene instructions delivered by a dental hygienist, and the same periodontal therapy as the intervention group after study completion (i.e., 6 months after randomization). The periodontal inflammation surface area was calculated using clinical attachment loss (CAL), periodontal probing pocket depth, and bleeding on probing. Cumulative probing depth was also measured. We examined the effect of periodontal therapy on periodontal outcomes and on clinical markers of disease activity in RA, as measured by the DAS28-C-reactive protein score as well as musculo-skeletal ultrasound grey scale and power Doppler scores. RESULTS: A total of 649 patients with RA were invited to participate in the study. Of these, 296 (46%) consented to participate in the screening visit. A sample of 201 patients was assessed for eligibility, of whom 41 (20%) did not meet the RA inclusion criteria and 100 (50%) did not meet the periodontal disease criteria. Among the 60 (30%) eligible participants, 30 were randomized to immediate periodontal therapy and 30 were allocated to the control group. The loss to follow-up was 18% at the end of the trial. There were no major differences with regard to baseline characteristics between the groups. Periodontal therapy was associated with reduced periodontal inflamed surface area, cumulative probing depths, RA disease activity scores, and ultrasound scores over the course of the trial. There was no change in CAL. CONCLUSIONS: Overall, the trial was feasible and acceptable to the study participants. Recruitment to and satisfactory retention in a randomized controlled trial on the effect of periodontal treatment on RA patients is possible, albeit challenging. In this feasibility study of patients with RA and periodontitis, periodontal treatment resulted in significant improvements in periodontal disease outcomes and overall RA disease activity, although complete resolution of periodontal inflammation was difficult to achieve in some cases.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. de Pablo P, Serban S, Lopez-Oliva I, et al. Outcomes of periodontal therapy in rheumatoid arthritis: The OPERA feasibility randomized trial. J Clin Periodontol. 2022. PMID: 36415901. doi:10.1111/jcpe.13756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。